The present invention relates to, in part, compositions comprising improved flagellin derived constructs and methods of using for vaccination, including adjuvants comprising flagellin-based agents.

Disclosed herein are compositions and methods related to mutant viruses, and in particular, mutant influenza viruses. The mutant viruses disclosed herein include a mutant M2 sequence, and are useful in immunogenic compositions, e.g., as vaccines. Also disclosed herein are methods, compositions and cells for propagating the viral mutants, and methods, devices and compositions related to vaccination.

A method for controlling dismutation in the synthesis of a heteroleptic triarylbismuthane is provided as are compounds produced by such a method and use of the same to inhibit the replication of microorganisms.

AAV vectors expressing anti-influenza antibodies are provided. Also described are pharmaceutical compositions useful in delivery same for prophylactic or anti-viral purposes. Methods of delivering such vectors are provided.

Fusion proteins comprising one or more portions of hepatitis virus core antigen (HBcAg) fused to immunogenic portions of influenza virus hemagglutinin (HA) protein, and nanoparticles (virus-like particles) formed from such proteins, nucleic acid molecules encoding such proteins, methods of making such nanoparticles, methods of using the disclosed nanoparticles to vaccinate an individual against influenza virus, and antibodies elicited by vaccination of a mammal with the disclosed nanoparticles.

Fusion proteins comprising one or more portions of hepatitis virus core antigen (HBcAg) fused to immunogenic portions of influenza virus hemagglutinin (HA) protein, and nanoparticles (virus-like particles) formed from such proteins, nucleic acid molecules encoding such proteins, methods of making such nanoparticles, methods of using the disclosed nanoparticles to vaccinate an individual against influenza virus, and antibodies elicited by vaccination of a mammal with the disclosed nanoparticles.

Disclosed are a crystal form and a salt form of a pyrazolopridine compound, and a preparation method therefor. Further included is the use of the crystal form in preparing anti-influenza virus drugs.

Disclosed are a crystal form and a salt form of a pyrazolopridine compound, and a preparation method therefor. Further included is the use of the crystal form in preparing anti-influenza virus drugs.

The present invention relates to nucleic acids of the general formula (I): (N.sub.uG.sub.lX.sub.mG.sub.nN.sub.v).sub.a and derivatives thereof as an immunostimulating agent/adjuvant and to compositions containing same, optionally comprising an additional adjuvant. The present invention furthermore relates to a pharmaceutical composition or to a vaccine, each containing nucleic acids of formula (I) above and/or derivatives thereof as an immunostimulating agent, and optionally at least one additional pharmaceutically active component, e.g. an antigenic agent. The present invention relates likewise to the use of the pharmaceutical composition or of the vaccine for the treatment of cancer diseases, infectious diseases, allergies and autoimmune diseases etc. Likewise, the present invention includes the use of nucleic acids of the general formula (I): (N.sub.uG.sub.lX.sub.mG.sub.nN.sub.v).sub.a and/or derivatives thereof for the preparation of a pharmaceutical composition for the treatment of such diseases.

Provided herein are anti-infective peptides and uses thereof. Such anti-infective peptides are useful against bacteria and viruses. Also provided herein are compositions comprising said anti-infective peptides.